Oxford Financial Group LTD. LLC Has $309,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Oxford Financial Group LTD. LLC lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 7.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,590 shares of the company’s stock after selling 310 shares during the quarter. Oxford Financial Group LTD. LLC’s holdings in Novo Nordisk A/S were worth $309,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Raymond James Financial Inc. bought a new stake in Novo Nordisk A/S in the 4th quarter valued at about $404,910,000. Sustainable Growth Advisers LP boosted its stake in shares of Novo Nordisk A/S by 23.6% in the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock valued at $459,416,000 after buying an additional 1,021,498 shares during the period. Amundi grew its position in Novo Nordisk A/S by 26.4% during the fourth quarter. Amundi now owns 3,311,456 shares of the company’s stock worth $283,615,000 after buying an additional 692,567 shares in the last quarter. Parnassus Investments LLC bought a new position in Novo Nordisk A/S during the 4th quarter worth $51,072,000. Finally, DAVENPORT & Co LLC raised its holdings in Novo Nordisk A/S by 75.1% in the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock valued at $90,477,000 after acquiring an additional 451,641 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on NVO shares. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Friday. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $76.88 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a 1 year low of $73.80 and a 1 year high of $148.15. The business has a 50 day moving average of $83.34 and a 200-day moving average of $101.22. The company has a market capitalization of $344.98 billion, a P/E ratio of 23.37, a P/E/G ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a $0.7874 dividend. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is currently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.